银屑病治疗暴露与COVID-19住院或院内死亡风险:法国队列研究
该研究基于法国国家健康保险数据库,纳入1 326 312例银屑病患者,评估第一波和第二波疫情期间不同治疗暴露与COVID-19住院或院内死亡的关系。结果显示,生物制剂等系统治疗未增加院内死亡风险,支持疫情期间维持系统治疗。
要点
- 生物制剂等系统治疗未增加COVID-19院内死亡风险。
- 第一波期间外用或非生物制剂治疗与住院风险轻度升高相关。
- 建议疫情期间维持银屑病系统治疗。
核心结论
- 银屑病系统治疗(包括生物制剂)与COVID-19院内死亡风险增加无关,支持疫情期间维持系统治疗。
研究设计与样本
- 基于法国国家健康保险数据库的队列研究,纳入2008至2019年注册的1 326 312例成人银屑病患者。
- 按基线治疗分为生物制剂、非生物制剂、外用治疗和无治疗四组,采用逆概率治疗加权Cox模型分析。
主要发现
- 第一波期间,3871例因COVID-19住院,759例(20%)院内死亡;第二波期间,3603例住院,686例(19%)院内死亡。
- 第二波期间,所有治疗暴露类型均与COVID-19住院风险相关。
- 任何治疗暴露类型均与COVID-19院内死亡无关。
临床怎么用
- 临床实践中,银屑病患者不应因担心COVID-19院内死亡而中断系统治疗(包括生物制剂)。
- 需关注第一波期间外用或非生物制剂治疗者住院风险轻度升高,但不应据此改变系统治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on treatment exposures for psoriasis and poor COVID-19 outcomes are limited. OBJECTIVES: To assess the risk of hospitalization or in-hospital mortality due to COVID-19 by treatment exposure in patients with psoriasis. METHODS: All adults with psoriasis registered in the French national health-insurance (Système National des Données de Santé, SNDS) database between 2008 and 2019 were eligible. Two study periods were considered: 15 February to 30 June 2020 and 1 October 2020 to 31 January 2021, the first and second waves of the COVID-19 pandemic in France, respectively. Patients were classified according to their baseline treatment: biologics, nonbiologics, topicals or no treatment. The primary endpoint was hospitalization for COVID-19 using Cox models with inverse probability of treatment weighting. The secondary endpoint was in-hospital mortality due to COVID-19. RESULTS: We identified 1 326 312 patients with psoriasis (mean age 59 years; males, 48%). During the first study period, 3871 patients were hospitalized for COVID-19 and 759 (20%) died; during the second period 3603 were hospitalized for COVID-19 and 686 (19%) died. In the propensity score-weighted Cox models, risk of hospitalization for COVID-19 was associated with exposure to topicals or nonbiologics [hazard ratio (95% confidence interval): 1·11 (1·04-1·20) and 1·27 (1·09-1·48), respectively] during the first period, and with all exposure types, during the second period. None of the exposure types was associated with in-hospital mortality due to COVID-19. CONCLUSIONS: Systemic treatments for psoriasis (including biologics) were not associated with increased risk of in-hospital mortality due to COVID-19. These results support maintaining systemic treatment for psoriasis during the pandemic.
引用
- Penso L, Dray-Spira R, Weill A, et al. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol. 2021. PMID: 34310699. doi:10.1111/bjd.20659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。